
US tariffs will have minimal impact on Indian pharma service companies like CDMOs: Report
It said «The companies see only marginal impact and no major disruption to US business from the planned US tariffs (10-25 per cent)».
The US remains a key market for Indian CDMO players, with exports worth approximately USD 9-10 billion annually. While the tariff proposal has raised concerns, Indian firms expect only a marginal impact on their business.
The report stated that India continues to play a crucial role in the US generic drug supply chain, providing Key Starting Materials (KSMs), Active Pharmaceutical Ingredients (APIs), and finished formulations. Indian companies supply nearly 40-45 per cent of the total generic drug volume in the US market.
It said «Export formulation players can majorly pass on any price impact from US tariffs to end customers. India caters to nearly approx. 40-45 per cent of the generic drug volumes in the US».
Artificial Intelligence(AI)
Java Programming with ChatGPT: Learn using Generative AI
By — Metla Sudha Sekhar, IT Specialist and Developer
Artificial Intelligence(AI)
Basics of Generative AI: Unveiling Tomorrows Innovations
By — Metla Sudha Sekhar, IT Specialist and Developer
Artificial Intelligence(AI)
Generative AI for Dynamic Java Web Applications with ChatGPT
By — Metla Sudha Sekhar, IT Specialist and Developer
Marketing
Performance Marketing for eCommerce Brands
By — Zafer Mukeri, Founder- Inara Marketers
Artificial Intelligence(AI)
Mastering C++ Fundamentals with Generative AI: A Hands-On
By — Metla Sudha Sekhar, IT Specialist and Developer
Finance
A2Z Of Money
By —
